Category Archives: Cancer

UACT ASKS CEOS FOR TRANSPARENCY ON CAR T TREATMENTS

Today, UACT submitted letters to the CEOs of three major pharmaceutical companies currently developing chimeric antigen receptor T-cell (CAR T) technologies.  UACT asked the leaders of Novartis, Gilead Sciences, and Juno Therapeutics to address questions regarding research and development (R&D) … Continue reading

Posted in Cancer, Drug prices, Gene Therapy, Patent, R&D, Uncategorized | Leave a comment

US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices

By Frederick M Abbott*, IP Watch | 31/05/2017 The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. … Continue reading

Posted in Cancer, Patent, R&D, Uncategorized | Leave a comment

Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs

Source: Knowledge Ecology International The Supreme Court’s decision in IMPRESSION PRODUCTS, INC. v. LEXMARK INTERNATIONAL, INC.  has clarified that the United States has world wide exhaustion of patent rights.   According to Professor Fred Abbott, who knows a lot about this issue, and … Continue reading

Posted in Cancer, Delinkage, ISDS, R&D, Uncategorized, USFDA | Leave a comment

Roche vs Indian Pharma: The battle for a cheaper cancer drug

By Divya Rajagopal, The Economic Times|May 14, 2017 Let’s hark back to the Nineties. The HIV-AIDS epidemic was spreading across Africa, leaving thousands dead, in spite of the existence of anti-retroviral drugs (ARVs). The cost of the treatment, around $10,000, … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Leave a comment

Update from India on Xtandi (Enzalutamide) for cancer treatment

In January 2016, KEI and the Union for Affordable Cancer Treatment petitioned the US the Department of Health and Human Services or the National Institutes of Health to use the federal government rights in the patents on the prostate cancer … Continue reading

Posted in Cancer, Drug prices, Patent, Uncategorized | Tagged , , , | Leave a comment

Competition Commission of India pulls up Roche for anti-competitive practices

By Jyotsna Singh, Scroll | April 27, 2017 In a landmark order, the commission has initiated an investigation into the multinational pharmaceutical company’s activities. The Competition Commission of India has initiated an investigation into Swiss pharmaceutical giant Roche for unfair … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , | Leave a comment

CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar

By Divya Rajagopal, The Economic Times | April 26, 2017 MUMBAI: The Competition Commission of India (CCI) will investigate Swiss drugmaker Roche over alleged attempts to block competitors from selling breast cancer drug Trastuzumab. The investigation has to be completed … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , , | Leave a comment